Project Grant HT9425261E127
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $750K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Grant Award Summary The Defense Health Agency awarded The Wistar Institute of Anatomy and Biology a $442,557 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 15, 2025, through September 14, 2028. The award funds research focused on immunotherapeutic targeting of SLC39A9 in CDKN2A-low melanoma, representing a translational research initiative designed to advance cancer immunotherapy approaches for military and public health benefit....
- Federal Project Grant Summary The Defense Health Agency (DHA) awarded The Wistar Institute of Anatomy and Biology a $1.10M Project Grant under the Military Medical Research and Development program (CFDA 12.420) for research titled "Immunotherapeutic Targeting of SLC39A9 in CDKN2A-Low Melanoma." The three-year award, effective September 15, 2025 through September 14, 2028, supports hypothesis-driven biomedical research designed to advance cancer immunotherapy approaches for melanoma....
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Institute For Cancer Research a $1,959,353 project grant effective September 1, 2025 through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). This award supports clinical research investigating pembrolizumab maintenance therapy following enfortumab vedotin/pembrolizumab induction treatment in front-line metastatic urothelial carcinoma. The research will be conducted at the...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University a $699,751 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2026, with a completion date of April 30, 2029. The award funds research to unveil mechanisms and develop innovative therapeutic interventions targeting ESR1-CCDC170 fusions in clinically aggressive, endocrine-resistant, and metastatic breast cancers. This research initiative represents the DHA's...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $621,779 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective April 1, 2026 through March 31, 2029. The award supports research titled "Modulating Immune Stress Pathways as a Strategy for CIPN Prevention and Cancer Management," which addresses chemotherapy-induced peripheral neuropathy (CIPN) prevention while advancing cancer...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $712,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, with completion targeted for August 31, 2027. The award funds the development of a GPC2 CAR T cell-amplifying extracellular vesicle vaccine, representing a translational immunotherapy research initiative aimed at advancing cancer...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded the University of Wisconsin–Madison a $1,074,650 project grant under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, with an ultimate completion date of August 31, 2029. The grant supports investigation of the immunomodulatory effects of chemokine signaling in renal cell carcinoma, representing a hypothesis-driven biomedical research initiative designed to advance innovative...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $934,501 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2028. The award supports research focused on developing peptide-centric chimeric antigen receptor (CAR) T-cell therapies for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute For Cancer Research a $533,308 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award funds research titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma," which investigates lymphocyte-activation gene 3 (LAG3) checkpoint inhibition as a therapeutic...